97 related articles for article (PubMed ID: 33376002)
1. The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei.
Lee H; Lee HH; Lim CY; Lee J
Surgery; 2021 May; 169(5):1213-1220. PubMed ID: 33376002
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer.
Shin SJ; Park S; Kim MH; Nam CM; Kim H; Choi YY; Jung MK; Choi HJ; Rha SY; Chung HC
Oncologist; 2019 Nov; 24(11):e1108-e1114. PubMed ID: 31015316
[TBL] [Abstract][Full Text] [Related]
3. HMGA1/HMGA2 protein expression and prognostic implications in gastric cancer.
Jun KH; Jung JH; Choi HJ; Shin EY; Chin HM
Int J Surg; 2015 Dec; 24(Pt A):39-44. PubMed ID: 26537313
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer.
Kong D; Su G; Zha L; Zhang H; Xiang J; Xu W; Tang Y; Wang Z
Med Oncol; 2014 Aug; 31(8):130. PubMed ID: 25037576
[TBL] [Abstract][Full Text] [Related]
5. High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma.
Fang CY; Liew PL; Chen CL; Lin YH; Fang CL; Chen WY
Anticancer Res; 2017 Apr; 37(4):1891-1899. PubMed ID: 28373457
[TBL] [Abstract][Full Text] [Related]
6. High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition.
Lee J; Ha S; Jung CK; Lee HH
Int J Oncol; 2015; 46(6):2431-8. PubMed ID: 25845850
[TBL] [Abstract][Full Text] [Related]
7. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of serum response factor is correlated with poor prognosis in patients with gastric cancer.
Yin J; Lv X; Hu S; Zhao X; Liu Q; Xie H
Hum Pathol; 2019 Mar; 85():10-17. PubMed ID: 30500416
[TBL] [Abstract][Full Text] [Related]
9. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Miyagi Y
Gastric Cancer; 2006; 9(2):106-13. PubMed ID: 16767366
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
Aydin D; Bilici A; Yavuzer D; Kefeli U; Tan A; Ercelep O; Mert A; Yuksel S; Ozcelik M; Isik D; Surmeli H; Odabasi H; Aliustaoglu M
Clin Transl Oncol; 2015 Aug; 17(8):604-11. PubMed ID: 25786367
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and recurrence pattern in node-negative advanced gastric cancer.
Lee IS; Yook JH; Kim TH; Kim HS; Kim KC; Oh ST; Kim BS
Eur J Surg Oncol; 2013 Feb; 39(2):136-40. PubMed ID: 23148932
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
13. REG4 promotes peritoneal metastasis of gastric cancer through GPR37.
Wang H; Hu L; Zang M; Zhang B; Duan Y; Fan Z; Li J; Su L; Yan M; Zhu Z; Liu B; Yang Q
Oncotarget; 2016 May; 7(19):27874-88. PubMed ID: 27036049
[TBL] [Abstract][Full Text] [Related]
14. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
15. Tissue
Sasahara M; Kanda M; Shimizu D; Tanaka C; Inokawa Y; Hattori N; Hayashi M; Nakayama G; Kodera Y
Anticancer Res; 2021 Feb; 41(2):609-617. PubMed ID: 33517265
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic profiling of gastric cancer tissues identified potential biomarkers for predicting peritoneal recurrence.
Kaji S; Irino T; Kusuhara M; Makuuchi R; Yamakawa Y; Tokunaga M; Tanizawa Y; Bando E; Kawamura T; Kami K; Ohashi Y; Zhang S; Orita H; Lee-Okada HC; Fukunaga T; Terashima M
Gastric Cancer; 2020 Sep; 23(5):874-883. PubMed ID: 32219586
[TBL] [Abstract][Full Text] [Related]
17. TPX2 expression is associated with poor survival in gastric cancer.
Tomii C; Inokuchi M; Takagi Y; Ishikawa T; Otsuki S; Uetake H; Kojima K; Kawano T
World J Surg Oncol; 2017 Jan; 15(1):14. PubMed ID: 28069036
[TBL] [Abstract][Full Text] [Related]
18. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.
Liu Z; Wu K; Yang Z; Wu A
Mol Cell Biochem; 2015 Nov; 409(1-2):155-62. PubMed ID: 26183485
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer.
Guo J; Zu G; Zhou T; Xing J; Wang Z
Clin Transl Oncol; 2015 Oct; 17(10):788-94. PubMed ID: 26022133
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression.
Binabaj MM; Soleimani A; Rahmani F; Avan A; Khazaei M; Fiuji H; Soleimanpour S; Ryzhikov M; Ferns GA; Bahrami A; Hassanian SM
Gene; 2019 Jul; 706():131-139. PubMed ID: 31055021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
